Skip to main content

Mylan's generic arthritis drug receives FDA approval

7/14/2010

PITTSBURGH The Food and Drug Administration has approved a generic arthritis treatment made by Mylan, the drug maker said Wednesday.


 


The FDA approved nabumetone tablets, a treatment for osteoarthritis and rheumatoid arthritis, in the 500 mg and 750-mg strengths.


 


 


Nabumetone tablets had sales of $68 million during the 12-month period ended in March, according to IMS Health. SmithKline Beecham, a predecessor company to GlaxoSmithKline, originally sold nabumetone tablets under the brand name Relafen, though Relafen no longer is available.


 


X
This ad will auto-close in 10 seconds